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Abstract
The use of botanical medicine by practitioners and the general public has dramatically
increased in recent years. Most of these botanical therapeutics are obtained through com-
mercial manufacturers or nutraceutical companies. The current standard of practice that
manufacturers typically use to standardize botanicals is done based on the level of a well-
known, abundant marker compound present in the botanical. This study evaluated the puta-
tive correlation between the level of a marker compound and the biological activity of eight
common botanicals. Overall, the standardization of a botanical based on a marker com-
pound was found not to be a reliable method when compared to in vitro bioactivity. A marker
compound is often not the biologically active component of a plant and therefore the level of
such a marker compound does not necessarily correlate with biological activity or therapeu-
tic efficacy.
Introduction
In the last three decades, botanical medicine has experienced a substantial growth in popular-
ity. In the United States, approximately 38% of adults and approximately 12% of children are
using some form of complimentary and alternative medicine (CAM). Of these, natural prod-
ucts, including botanicals, are the most common form of CAM therapy used [1]. Worldwide,
the World Health Organization estimates that 80% of people rely on herbal medicines for some
part of their primary health care [2]. In Australia, Canada, USA, Belgium, and France, it is esti-
mated that 48%, 70%, 42%, 38%, and 75% of people, respectively, have used herbal medicines
at least once for their healthcare needs [3,4]. Much of the driving force behind this desire for
herbal medicine is associated with public dissatisfaction with the cost of prescription medica-
tions, concerns over potential side-effects with conventional medications, and a growing inter-
est in natural or organic remedies.
As phytotherapeutics continue to gain popularity in global markets, increased oversight and
means of quality control become paramount to ensuring the medicinal value and activity of
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therapeutic botanicals. Standardization, a concept modelled largely from the pharmaceutical
industry involving the identification of an active constituent or marker compound, has been
adopted by both nutraceutical companies and government agencies as a means for quality con-
trol of phytotherapeutics [5,6,7,8]. This approach seeks to establish the level of a single phyto-
chemical biomarker within a species to hopefully predict for the pharmacological bioactivity of
botanical supplements. Although a commonly accepted practice for quality assurance in the
nutraceutical market, limited research has evaluated standardization using a single marker
compound as an efficacious model of overall product quality in terms of bioactivity and
potency.
Unlike a conventional pharmaceutical product which usually contains a single defined
chemical, botanical extracts contain mixtures of multiple components. Different preparations
for the same species of plant may vary in their chemical profile dependent upon geographical
area, seasonal variations, method of harvest, extraction procedures, and/or storage conditions
[5,6,8,9]. In addition, a botanical extract may contain numerous active constituents which may
act synergistically or target multiple conditions or diseases. Very few botanicals with observed
therapeutic effects have well-defined ‘active components’ which have been chemically identi-
fied. Due to this, a marker compound, which is a constituent having an established chemical
structure, is accepted as the industry standard for quality control of nutraceuticals even if that
compound is not directly involved in the biological activity of the herb.
This study sought to explore the relationship or correlation between the standard marker
compound from selected botanical species and the predictive efficacy based on in vitro
bioactivity.
Materials and Methods
Botanical selection and preparation
The botanicals selected for this study were selected based on their established antibacterial,
antifungal, antiviral or immune-stimulatory activity. Dried plant material was obtained from
reputable sources with documentation of authenticity. All plant material was subsequently ver-
ified by qualified botanical specialists using herbal pharmacopoeia monographs and reference
keys. A voucher specimen of all plant material was deposited in a repository. For tincture prep-
aration, the dried botanicals were ground to a fine powder, resuspended in extraction solution
and incubated for 3 days at room temperature. The extract was centrifuged at 3000 x g for 10
min to remove cell debris and the extraction solution filtered through a 0.2 micrometer filter.
For standardization and comparison, all botanical extracts had an average non-volatile constit-
uent concentration averaging 38.4 mg/ml (ranging from 28.4–42.6 mg/ml). This concentration
(mg/ml) is based on the weight of non-volatile constituents present in the extract per ml of
aqueous liquid. The source, extraction solution, and plant solid to liquid ratio (grams:ml)
include: Turnera diffusa (Starwest botanicals [Sacramento, CA], AmeriHerb [Ames, IA],
Mountain Rose [Eugene, OR] 1:4 leaf extract with 63% ethanol, 27% water, 10% glycerin),
Eucalyptus globulus (Starwest botanicals [Sacramento, CA], AmeriHerb [Ames, IA], Mountain
Rose [Eugene, OR] 1:3 leaf extract with 53% ethanol, 42% water, 5% glycerin), Cinnamomum
zeylanicum (Starwest botanicals [Sacramento, CA], AmeriHerb [Ames, IA], Mountain Rose
[Eugene, OR] 1:8 bark extract with 65% ethanol, 35% water); Piper cubeba (Starwest botanicals
[Sacramento, CA], Dragon herbarium [Ames, IA], Nature’s Wonderland [Eugene, OR] 1:8
berry extract with 60% ethanol, 40% water), Hypericum perforatum (Starwest botanicals [Sac-
ramento, CA], AmeriHerb [Ames, IA], Mountain Rose [Eugene, OR] 1:4 leaf extract with 58%
ethanol, 32% water, 10% glycerin), Glycyrrhiza glabra (Starwest botanicals [Sacramento, CA],
AmeriHerb [Ames, IA], Mountain Rose [Eugene, OR] 1:6 root extract with 26% ethanol, 10%
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glycerin, 64% water), Echinacea purpurea (Starwest botanicals [Sacramento, CA], AmeriHerb
[Ames, IA], Mountain Rose [Eugene, OR], 1:5 leaf/flower extract with 25% ethanol, 75%
water), Astragalus membranaceus (Starwest botanicals [Sacramento, CA], AmeriHerb [Ames,
IA], Mountain Rose [Eugene, OR] 1:5 root extract with 25% ethanol, 75% water).
Marker compound analysis: The analytical measurement of marker compound levels was
done commercially by ChromaDex (Irvine, CA) for each botanical using standard procedures.
An Agilent 1100 Series system was used and all samples compared to the known reference stan-
dards. Analytes (marker compounds) chosen to be measured were based on established identifi-
cation and characterization of each marker compound within each herb. An analytical test
report was obtained for each sample and the percent value for the desired analyte (marker com-
pound) reported relative to the weight of the entire sample. The analytes for each botanical
included: Eucalytpus globulus (marker compound: eucalyptol), Turnera diffusa (marker com-
pound: arbutin), Glycyrrhiza glabra (marker compound: glycyrrhizic acid),Hypericum perfora-
tum (marker compound: hyperforin), Cinnamomum burmanii (marker compound: coumarin),
Piper cubeba (marker compound: piperine), Echinacea purpurea (marker compounds: caftaric
acid, echinacoside and cichoric acid), and Astragalus membranaceus (marker compound: astra-
galoside I).
Anti-bacterial assay
Media and the bacterial culture Staphylococcus aureus ATCC 11632 were obtained from Hardy
Diagnostics (Santa Monica, CA). For minimum inhibitory concentration (MIC) determina-
tion, 18-hour cultures (ranging from 1-5x108 colony forming units (CFU)/ml) were diluted
into media (1:1,000 dilution; tryptic soy broth (TSB)) followed by the addition of varying con-
centrations of each botanical extract. The cultures were incubated at 37°C with aeration (by
continuous rotation) for 24 hours. The MIC value was determined as the dose of the botanical
extract required to completely inhibit replication of the bacteria (as measured by a lack of tur-
bidity absorbance.
Anti-fungal assay
Media and the yeast culture Candida albicans ATCC 10231 were obtained from Hardy Diag-
nostics (Santa Monica, CA). For growth studies, 18-hour cultures (ranging from 3-8x107 col-
ony forming units (CFU)/ml) grown at 30°C in YPD broth were diluted into media (1:1,000
dilution; yeast peptone dextrose broth (YPD with 5% fetal bovine serum)) followed by the
addition of varying concentrations of each botanical extract. For hyphal growth assessment,
the cultures were incubated 37°C with aeration (by continuous rotation) for 24 hours. At 24
hours post-treatment, light microscopy was done to evaluate the morphological state of the C.
albicans. Each broth culture was stained with Lactophenol Cotton Blue and visualized by light
microscopy. A minimum of 100 cells were counted and the percent of single cells verses
hyphal/pseudohyphal cells determined.
Anti-viral assay
HSV1 KOS (a kind gift from David Bloom, Univ. of Florida College of Medicine). Vero cells
(ATCC) were maintained with Minimal Essential Media (Cellgro) supplemented with 100 IU
penicillin/ml, 100 microgram streptomycin/ml, 2.5 microgram amphotericin B/ml, and 10%
heat-inactivated fetal bovine serum (Hyclone). Cells were incubated at 37°C, 5% CO2 in a
humidified chamber. Plaque reduction assays were performed by diluting virus stocks and pre-
incubating 100–200 plaque-forming units (pfu) with increasing concentrations of botanicla
extract for 20 minutes. Monolayers were infected for 1 hour at 37°C followed by incubation in
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media containing the botanical for 3 days at 37°C. Plaques were visualized by staining with
0.1% crystal violet in 20% ethanol.
Immune-stimulatory assay
Human PBMCs were obtained from freshly drawn blood. To obtain the fresh PBMCs, blood
was collected by venipuncture into heparinized tubes. Whole blood was removed and added to
an equal volume of balanced salt solution (0.01% D-glucose, 0.005 mM CaCl2, 0.098 mM
MgCl2, 0.54 mM KCl, 14.5 mM Tris pH 7.6, 126 mMNaCl). Forty mls of blood/salt solution
was layered on top of 10 mls Ficoll-Paque Plus (Amersham Biosciences) and centrifuged at
400×g for 40 minutes at 20°C. PBMCs were removed from the interface and washed in bal-
anced salt solution. The collection of fresh PBMCs was approved by the Arizona State Univer-
sity and Southwest College of Naturopathic Medicine (SCNM) Institutional Review Boards. All
participants signed a written informed consent form (approved by the SCNM Institutional
Review Board) prior to participation. PBMCs were resuspended in RPMI1640 with 10% fetal
bovine serum (1×106 cells/mL) in cell culture dishes. 1×107 cells (in 10 mL media) were treated
with botanical extract for 18 hours. Following treatment, total RNA was isolated and purified
as per manufacturer’s protocol using an RNeasy kit (Qiagen). Briefly, the cell lysate was
homogenized using a QIAshredder spin column. Any DNA contamination was eliminated by
DNase digestion and the RNA was isolated using the RNeasy spin column. Quantitative real-
time PCR (qPCR) was performed using iQSYBR Green Super mix (Bio-Rad). Briefly, cDNA
template for each isolate was added to wells containing PCR reaction mix (iQSYBR Green
Super mix and primers). Primers were obtained from SABiosciences. Reactions were done in a
MiniOpticon real-time PCR detection system with CFXManager software control (Bio-Rad).
All samples were normalized to GAPDH [10].
Statistical analysis
SPSS™ statistical software was used to analyze the data. Comparing marker compound with
biological activity values, including the three (3) “Sources”, a Paired T-test was used. Further
analysis was done to determine individual group cause and effect relationships between
“Marker Compound” and “Biological Activity”. A regression line comparison (Co-Variance)
was computed compared to a “CONTROL” regression line on each of the botanicals.
Results
Dried herbal samples were obtained from three different reputable, commercial sources. Each
species of herb was extracted under the same conditions. Fig 1 illustrates the marker compound
level and in vitro bioactivity results for the antiviral herbs, Glycyrrhiza glabra and Hypericum
perforatum. As shown in Fig 1A, the level of the each marker compound varied substantially
between the different sources with glycyrrhizic acid at 3.2%, 1.37% and 0.14% of the relative
weight of the sample, and hyperforin at 0.059%, 0.026% and 1.47%. Antiviral activity of the
extracts was measured as the dose required to inhibit herpes simplex-1 (HSV-1) plaque forma-
tion by 50% (ID50). For G. glabra, the ID50 was reasonably consistent between all three samples
(or commercial sources), even though the level of glychyrrhic acid was highly variable (Fig 1A
and 1B). For H. perforatum, the viral ID50 varied between the samples, but did not correlate
well with the level of hyperforin (Fig 1A and 1B). These results support that the marker com-
pound for these herbs is not a reliable measure of antiviral activity associated with these herbs
and that these individual compounds are not likely involved in this bioactivity.
For comparison to antibacterial activity, Eucalyptus globulus and Turnera diffusa were
selected based on their historical use [11,12,13]. As shown in Fig 2A, the levels of eucalyptol in
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Fig 1. Marker compound level and bioactivity of antiviral herbs. Part A) Marker compound level (percent
of total weight) of glycyrrhizic acid (fromG. glabra) and hyperforin (fromH. perforatum) and HSV-1 ID50
values (μl/ml) are shown from three commercial sources. Part B) Marker compound ratios and bioactivity
ratios were normalized to 100 (max. level) and graphed.
doi:10.1371/journal.pone.0159857.g001
Fig 2. Marker compound level and bioactivity of antibacterial herbs. Part A) Marker compound level
(percent of total weight) of eucalyptol (from E. globulus) and arbutin (from T. diffusa) and Staphylococcus
aureusMIC values (microliters/ml) are shown from three commercial sources. Part B) Marker compound
ratios and bioactivity ratios were normalized to 100 (max. level) and graphed.
doi:10.1371/journal.pone.0159857.g002
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the samples were at 0.437%,<0.038% and 0.533%, and arbutin at 0.435%, 0.351% and 1.33%.
Again, these results suggest that significant differences exist between the levels of each marker
compound when herbs are obtained from varying sources. Antibacterial activity was measured
as the dose of each extract required to obtain the MIC (minimum inhibitory concentration).
As shown, eucalyptol appeared to illustrate a positive correlation between the antibacterial
activity and the marker compound level (Fig 2B). Similarly, although not as correlative, extracts
from T. diffusa appeared to demonstrate that as changes in arbutin levels were observed, fairly
similar changes in antibacterial activity occurred (Fig 2B). These results suggest that level of
eucalyptol may be an effective measure of antibacterial activity associated with E. globulus, and
that either eucalyptol, or another compound that varies similarly, may be involved in this
response. For T. diffusa, the results suggest that arbutin may be involved in the antibacterial
activity associated with this herb, however additional constituents may be involved as well
based on the observed differences between Source 1 and Source 2 (Fig 2B).
The activity and marker compound levels of the antifungal herbs, Cinnamomum burmanii
and Piper cubeba are shown in Fig 3. Our lab has previously demonstrated that these herbs can
block the differentiation of Candida albicans from a single-celled yeast form to a multicellular
hyphal form (data not shown). Bioactivity was measured as the concentration of the extracts
required to inhibit C. albicans hyphal formation by 50% (ID50). As shown in Fig 2A, courmarin
levels in C. burmanii varied between 0.075%, 0.113% and 0.088%, whereas piperine levels in P.
cubeba varied between 0.082%, 0.008% and non-detectable (<0.009%). In comparison of the
marker compound levels to bioactivity of C. burmanii, Source 1 and Source 2 agreed well, but
Source 3 demonstrated only a weak correlation (Fig 2B). For P. cubeba, the marker compound
level did not correlate with bioactivity, with Source 3 having the lowest piperine level, but the
highest bioactivity (Fig 2B). Again, these results suggest that piperine is not a reliable measure
Fig 3. Marker compound level and bioactivity of antifungal herbs. Part A) Marker compound level
(percent of total weight) of courmarin (from C. burmanii) and piperine (from P. cubeba) andCandida albcians
hyphal growth ID50 values (microliters/ml) are shown from three commercial sources. Part B) Marker
compound ratios and bioactivity ratios were normalized to 100 (max. level) and graphed.
doi:10.1371/journal.pone.0159857.g003
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of the antifungal activity of P. cubeba and is likely not involved in the antifungal bioactivity
associated with this herb, whereas, for C. burmanii, courmarin had a weak correlation with bio-
activity making it a questionable measure for therapeutic value.
Lastly, immune-stimulatory herbs were selected including Echinacea purpurea and Astagu-
lus membranaceus. For E. purpurea, three different marker compounds were measured includ-
ing caftaric acid, echinacoside, and cichoric acid [14]. As shown in Fig 4A, the percentage of all
these compounds varied dramatically between the three samples, with the highest levels of all
three compounds present in Source 2 and the lowest levels in Source 3. For bioactivity, the abil-
ity of the E. purpurea extracts to induce interferon-gamma (IFN-gamma) and interleukin-
1beta (IL1beta) mRNA synthesis in PBMCs was determined. As shown in Fig 4B, the bioactiv-
ity measure for either IFNgamma or IL1beta synthesis did not correlate with any of the three
marker compounds. This result can most easily been observed in Source 3 which had the high-
est bioactivity, but lowest marker compound levels (Fig 4B). For A.membranaceus, the level of
astragaloside I varied between 0.059%, 0.103% and 0.065% (Fig 4A). For bioactivity, the ability
of A.membranaceus extracts to induce IL-6 and IL-8 mRNA levels in PBMCs was determined.
As shown in Fig 4B, similar results to E. purpurea were obtained with A.membranaceus with
no clear correlation of bioactivity to marker compound levels.
Initial observation of the results suggests that, for the majority of botanicals tested, a strong
correlation did not exist between the marker compound level and the measured bioactivity.
Statistical analysis of the samples compared as a whole indicated a significant difference
(p< 0.04) supporting that the level of a marker compound is not a consistent indicator of bio-
activity. Repeated Measures ANOVA was also used to analyze and compare the three Sources.
Fig 4. Marker compound level and bioactivity of immune-stimulatory herbs. Part A) Marker compound level
(percent of total weight) of cafteric acid, echinacoside and cichoric acid (from E. purpurea) and astragaloside I
(from A.membranaceus) and cytokine induction values (relative to untreated) are shown from three commercial
sources. Part B) Marker compound ratios and bioactivity ratios were normalized to 100 (max. level) and graphed.
doi:10.1371/journal.pone.0159857.g004
Bioactive Predictability for Marker Compounds
PLOS ONE | DOI:10.1371/journal.pone.0159857 July 26, 2016 7 / 10
A statistically significant difference between the three Sources of p< 0.0019 was determined,
which may additionally contribute to the disparity between the marker compound level and
bioactivity.
Further analysis was required to determine individual group cause and effect relationships
between the marker compound level and bioactivity of selected indicators. Therefore, a regres-
sion line comparison (Co-Variance) was computed compared to a control regression line
(y = 1x + 0) on each of the botanicals, As shown in Fig 5, the control line in each graph repre-
sents a perfect 1:1 cause and effect relationship. As supported by Fig 2, E. globulus demon-
strated the strongest cause and effect relationship between the marker compound level and
bioactivity (Fig 5C). Similarly, T. diffusa and C. burmanii demonstrated a weaker, but possible
correlation between the marker compound level and bioactivity (Fig 5D and 5E). For the
majority of herbs and all other herbs tested, no cause and effect correlation was observed
between the marker compound level and bioactivity, with G. glabra,H. perforatum, E. pur-
purea, and A.membranaceus having a significant p< 0.05 supporting a significant difference
(Fig 5).
Discussion
Botanical extracts are composed of numerous constituents or compounds. The amount of each
of the specific compounds present in a botanical extract depends on a number of factors
including time of harvest, geographical region, agricultural methods, extraction process, and
storage methods. For this study, eight different herbs were obtained from three different com-
mercial sources. The initial characterization of these herbs demonstrated substantial variations
in levels of the marker compound present in each herb from each of the three sources. As pre-
viously noted, the differences observed were likely attributed to environmental variations since
all extracts were prepared similarly. When tested for in vitro bioactivity the results generally
demonstrated a lack of correlation between the variation in marker compound level and the in
vitromeasured bioactivity.
Fig 5. Regression analysis of marker compound level versus bioactivity. A regression line comparison (Co-Variance) between
the marker compound level and bioactivity of each botanical is shown. A “CONTROL” regression line representing a 1:1 cause and
effect relationship is shown for comparison. The p-value representing the statistical difference between the marker compound level
and bioactivity is shown.
doi:10.1371/journal.pone.0159857.g005
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The strongest outlier with possible attributable predicative ability between the marker com-
pound level and bioactivity was E. globulus. Eucalyptol is the main component in the Eucalyp-
tus essential oil with well-established antibacterial properties [12]. The results showed an
overall positive relationship of increased bioactivity as percentage of marker compound
increased (Figs 2B and 5C). The established and well documented antibacterial activity of euca-
lyptol paired with these results suggests the predictive ability of eucalyptol related to the anti-
bacterial bioactivity of E. globulus. For T. diffusa and C. burmanii, a weaker but significant
cause and effect relationship was observed between the marker compound level and tested bio-
activity. These results suggest that the marker compound measured for these herbs may be
involved in the bioactivity, or the activity may involve synergism with additional constituents,
or that another, unrelated compound is involved in the bioactivity and follows similar levels as
that of the marker compound tested. These unclear correlations with bioactivity make the level
of a marker compound questionable as a measure for therapeutic value.
For the majority of botanicals tested, including G. glabra, H. perforatum, P. cubeba, E. pur-
purea and A.membranaceus, the level of the marker compound did not correlate with the
tested bioactivity. The concept of botanical standardization using a marker compound is widely
accepted as the standard criteria for consistency, quality control, and efficacy of herbal prepara-
tions and products [6,7,8,15,16]. The results presented suggest that standardization using a
marker compound is not an accurate prediction model for bioactivity. For many herbal prod-
ucts, therapeutic use may be related to the treatment of multiple health conditions. As shown
for E. globulus, if a marker compound like eucalyptol is shown to correlate with bioactivity,
standardization using this method may be warranted. However, for the case of E. globulus, this
may only be related to the antibacterial efficacy for this herb. For most botanicals, the specific
bioactive constituents have not been identified. Furthermore, phytotherapeutics with multiple
therapeutic uses likely contain several different active constituents or contain compounds
which work synergistically to produce the desired therapeutic effects. The results presented
suggest that standardization of botanical products should be done by an alternative method
other than measuring a marker compound which has not been identified as the active constitu-
ent. The direct measurement of bioactivity and/or levels of a marker constituent known to be
involved in the bioactivity likely offers a more reliable measure of efficacy. However, in vitro
assays for bioactivity for standardization should be confirmed in in vivomodel systems as well.
In the meantime, until active constituents are identified, in vitro bioactivity assays may provide
an improved system for evaluating the efficacy and quality assurance in the use of botanical
supplements.
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